Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include GlobeNewswire, Reuters, Endpoints News and Fierce Biotech. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Quick answers
Why is "Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Ipsen to pay $1.75B for Kartos and its blood cancer asset FirstWord Pharma · 7h ago
- Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline GlobeNewswire · 7h ago
- French biotech company Ipsen to buy Kartos Therapeutics for $450 million Reuters · 7h ago
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront Endpoints News · 7h ago
- Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis Fierce Biotech · 7h ago
- Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion WSJ · 7h ago
Topics
Related trends
Microsoft’s $570 Billion Rout Sets Up Its Worst Month Since 2000
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
AI Rout Exposes Wall Street’s $270 Billion Speculation Machine
A sharp sell-off in AI assets has turned the spotlight on Wall Street's speculative practices and triggered warnings about market leverage.
Best Buy launches massive anti-Prime Day sale
Best Buy has launched its Tech Fest sale, offering widespread consumer electronics discounts timed to coincide with Prime Day.
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Intel, Micron, SpaceX, Apogee Therapeutics, and More Stocks That Explain Today’s Market
Market analysts are tracking shifting volatility and AI-driven growth as investors focus on semiconductor and aerospace stocks.
Coke Takes on IRS With $20 Billion at Stake
Coca-Cola faces a significant legal challenge as a $20 billion tax dispute with the IRS moves to a federal appeals court.